Sign In
Buy APGN
$0.385
+0 (+0%)
At Close: Nov 22, 2023
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Apexigen, In
- Marked increases in overall survival observed across soft tissue sarcoma patients - - Demonstrated improvement of median progression free survival in patients with dedifferentiated liposarcoma (DDLP
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Apexigen, In
Apexigen (APGN) to Get Acquired by Pyxis Oncology, Stock Up
04:32pm, Thursday, 25'th May 2023
Apexigen (APGN) surges as Pyxis Oncology offers to acquire it for approximately $16 million.
Shareholder Alert: Ademi LLP investigates whether Apexigen, Inc. has obtained a Fair Price in its transaction with Pyxis Oncology
10:34am, Wednesday, 24'th May 2023
MILWAUKEE , May 24, 2023 /PRNewswire/ -- Ademi LLP is investigating Apexigen (Nasdaq: APGN) for possible breaches of fiduciary duty and other violations of law in its transaction with Pyxis Oncology.�
Why Is Apexigen (APGN) Stock Up 31% Today?
09:43am, Wednesday, 24'th May 2023
Apexigen (NASDAQ: APGN ) stock is rising higher on Wednesday following news of a deal with Pyxis Oncology (NASDAQ: PYXS ). This deal has Pyxis Oncology agreeing to acquire Apexigen for 0.1725 shares o
APGN Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Apexigen, Inc. Is Fair to Shareholders
08:16am, Wednesday, 24'th May 2023
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Apexigen, Inc. (NASDAQ: APGN) to Pyxis Oncology, Inc. for 0.1725 shares of Pyxis for each
Are Medical Stocks Lagging Apexigen, Inc. (APGN) This Year?
11:18am, Friday, 03'rd Mar 2023
Here is how Apexigen, Inc. (APGN) and Atara Biotherapeutics (ATRA) have performed compared to their sector so far this year.
Apexigen Announces Review of Strategic Alternatives and Restructuring
08:00am, Monday, 27'th Feb 2023
SAN CARLOS, Calif., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Apexigen, Inc. (Nasdaq: APGN) a clinical-stage company focused on developing innovative antibody-based therapeutics for the treatment of cancer wi
Is Apexigen, Inc. (APGN) Stock Outpacing Its Medical Peers This Year?
11:18am, Wednesday, 15'th Feb 2023
Here is how Apexigen, Inc. (APGN) and BeiGene, Ltd. (BGNE) have performed compared to their sector so far this year.
4 Penny Stocks To Buy According To Analysts & Targets Over 600%
09:33am, Wednesday, 25'th Jan 2023
Analysts have put these on their list of penny stocks to buy. Do you agree?
Apexigen Announces Approximately $2.8 Million Private Placement Financing
08:30am, Tuesday, 24'th Jan 2023
SAN CARLOS, Calif., Jan. 24, 2023 (GLOBE NEWSWIRE) -- Apexigen, Inc. (Nasdaq: APGN), a clinical-stage company focused on developing innovative antibody-based therapeutics for the treatment of cancer w
4 Penny Stocks To Buy According To Insiders & Targets Up To 347%
09:29am, Thursday, 19'th Jan 2023
Penny stocks to buy according to analysts. The post 4 Penny Stocks To Buy According To Insiders & Targets Up To 347% appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.co
Apexigen Announces New Phase 2 Data Evaluating Sotigalimab, its CD40 Agonist Antibody, at ASCO Gastrointestinal Cancers Symposium 2023
08:00am, Thursday, 19'th Jan 2023
-Results demonstrate sotigalimab's ability to turn immunologically “cold” tumors “hot” to increase anti-tumor immune responses for increased therapeutic effect in patients with esophageal/gast
Apexigen Stock Soars After Analyst Rating, Is It Time to Buy?
02:39pm, Tuesday, 10'th Jan 2023
Apexigen stock is soaring after a bullish analyst rating. This can frequently give penny stocks legitimacy, but only if the stock can hold these gains.
